Xponance, Inc. Agenus Inc Transaction History

Xponance, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.53 - $0.93 $453 - $795	855 Added 3.86%	23,010 $13,000
Q4 2023 Jan 31, 2024	BUY	$0.63 - $1.14 $1,110 - $2,009	1,763 Added 8.65%	22,155 $18,000
Q3 2023 Oct 23, 2023	BUY	$1.12 - $1.88 $585 - $983	523 Added 2.63%	20,392 $23,000
Q2 2023 Jul 13, 2023	BUY	$1.31 - $2.04 $3,196 - $4,977	2,440 Added 14.0%	19,869 $31,000
Q4 2022 Jan 23, 2023	BUY	$2.02 - $3.25 $2,977 - $4,790	1,474 Added 9.24%	17,429 $0
Q3 2022 Oct 24, 2022	BUY	$1.96 - $3.14 $2,994 - $4,797	1,528 Added 10.59%	15,955 $33,000
Q2 2022 Aug 02, 2022	BUY	$1.3 - $2.64 $5,202 - $10,565	4,002 Added 38.39%	14,427 $28,000
Q1 2022 Apr 20, 2022	BUY	$2.35 - $3.47 $230 - $340	98 Added 0.95%	10,425 $26,000
Q4 2021 Jan 31, 2022	BUY	$2.92 - $5.74 $30,154 - $59,276	10,327 New	10,327 $33,000
Q3 2021 Nov 05, 2021	SELL	$4.98 - $6.63 $53,749 - $71,557	-10,793 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$2.56 - $5.49 $27,630 - $59,253	10,793 New	10,793 $59,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

Stay updated on Xponance, Inc. with notifications on news.